Work

Evaluation of rapid diagnostic detection methods for a range of clinically significant antigens /

Year: 2023
Type: dissertation
Abstract: Accurate and timely diagnosis is essential in the management and treatment of any disease. Point of care testing is used to generate a result quickly, so that appropriate care and treatment can be implemented. The research in this thesis focused on the development, evaluation, and optimisation of diagnostic methods at a point of need level, for detection of a range of biomarkers - NGAL, MAP Protoplasmic antigen (PPA) and a conserved sequence for the detection of group B streptococcus (proprietary, HiberGene Diagnostics), using two different rapid diagnostic methods; LFIA and LAMP technology. Work on an NGAL LFIA assay resulted in the development of a reliable biotinylated goat IgG control line, that was consistently detected throughout the study. Several LFIA formats were investigated for the detection of an NGAL test line. A successful NGAL competitive/inhibition assay was developed, however, the assay performed poorly during repeatability and reproducibility testing and further work is needed. An LFIA for detection of Mycobacterium Paratuberculosis (MAP) through detection of MAP Protoplasmic antigen (PPA) was also investigated. Two working control lines were developed using bovine IgG and rabbit anti-sheep antibody. It did, however, prove difficult to develop a PPA test line and investigations failed to elucidate the underlying cause. Further exploratory studies to explore the purity of the PPA antigen may prove central to progression of this work. A GBS-UNG LAMP assay for the detection of group B streptococcus (GBS) was developed to replace the existing assay formulation currently employed by HiberGene Diagnostics. The results of this study indicate that the incorporation of UNG has the ability to degrade carry over amplicon at a concentration of 3x104 CFU/ml in a simulated clinical sample. The development of the new GBS-UNG assay also led to an improved formulation and performance of the existing GBS-dTTP based assay in terms of sensitivity, time of detection, and contamination control. This study provides the basis for further development of these LFIA assays for detection of NGAL and MAP. In the future these assays could provide an opportunity for early detection which would aid in decisions regarding treatment plans and potentially affect prognosis. In addition, the new formulation for the GBS assay may be adopted by industry to improve current testing methods, most notably preventing carryover contamination.
Language: English
Open Access status: green
OpenAlex ID: W7133071998
Cites: 153
Cited by:
Related to: 9